07 January 2010

Genetic Clues May Point to Better Lymphoma Treatments

Findings could help those with a type of non-Hodgkin's lymphoma, researchers say


This article has not necessarily been edited by Health24.

WEDNESDAY, Jan. 6 (HealthDay News) -- New research into the genetic causes of a form of non-Hodgkin's lymphoma could lead to novel treatments, suggest researchers from the U.S. National Institutes of Health.

Their new study reports on how lymphoma cancer cells manage to survive. The type of cancer in question, known as diffuse large B-cell lymphoma, develops in B cells, which are part of the immune system and help the body fend off attackers.

Diffuse large B-cell lymphoma accounts for about a third of newly diagnosed non-Hodgkin's lymphoma cases, the researchers noted in a news release from the U.S. National Cancer Institute.

The research, published Jan. 7 in Nature, pinpoints how signaling pathways work within lymphoma cells to allow them to survive. The researchers also explored genetic mutations that play a role in the process.

"This study opens up a wealth of therapeutic opportunities for this type of lymphoma and may eventually lead to clinical trials testing agents that target components of the B-cell receptor signaling pathway," the study's senior author, Dr. Louis M. Staudt, of the National Cancer Institute's Center for Cancer Research, said in the news release.

The researchers suggested that dasatinib, a drug that has been approved for treatment of chronic myelogenous leukemia, could turn off the signaling process.

More information

The American Cancer Society has more on non-Hodgkin's lymphoma.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules